Mario Delgado

List of Publications by Year in Descending Order

180 papers	11,603 citations	64 h-index	101 g-index
189 ext. papers	12,541 ext. citations	6.5 avg, IF	6.23 L-index

#	Paper	IF	Citations
180	THE NEUROPEPTIDE CORTISTATIN REGULATES DERMAL AND PULMONARY FIBROSIS IN AN EXPERIMENTAL MODEL OF SYSTEMIC SCLEROSIS. *Neuroendocrinology*, **2021**,	5.6	1
179	Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease. *Nature Communications*, **2021**, 12, 1869	17.4	7
178	The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury. *Pharmaceutics*, **2021**, 13,	6.4	1
177	Protective role of cortistatin in pulmonary inflammation and fibrosis. *British Journal of Pharmacology*, **2021**, 178, 4368-4388	8.6	2
176	Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases. *European Journal of Medicinal Chemistry*, **2021**, 223, 113655	6.8	4
175	Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity **2020**, 8,		5
174	Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in preclinical models of hematopoietic reconstitution and severe colitis. *Haematologica*, **2019**, 104, e54-e58	6.6	9
173	Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune Responses. *Journal of Immunology*, **2018**, 200, 3697-3710	5.3	15
172	Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2018**, 146, 123-138	6.8	43
171	The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia. *Journal of Neuroinflammation*, **2018**, 15, 343	10.1	5
170	Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. *Experimental and Molecular Medicine*, **2017**, 49, e290	12.8	16
169	Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells. *Scientific Reports*, **2017**, 7, 46444	4.9	19
168	Role of Cortistatin in the Stressed Immune System. *Frontiers of Hormone Research*, **2017**, 48, 110-120	3.5	7
167	The neuropeptide cortistatin attenuates experimental autoimmune myocarditis via inhibition of cardiomyogenic T cell-driven inflammatory responses. *British Journal of Pharmacology*, **2017**, 174, 267-280	8.6	14
166	Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. *Experimental Hematology*, **2017**, 45, 85-93.e2	3.1	8
165	Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features. *Journal of Tissue Engineering and Regenerative Medicine*, **2017**, 11, 2895-2911	4.4	66
164	Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. *Stem Cells International*, **2017**, 2017, 2389753	5	27

163	Ghrelin and adipose-derived mesenchymal stromal cells improve nerve regeneration in a rat model of epsilon-caprolactone conduit reconstruction. *Histology and Histopathology*, **2017**, 32, 627-637	1.4	4
162	Immunobiology of the Pituitary Adenylate Cyclase-Activating Peptide. *Current Topics in Neurotoxicity*, **2016**, 691-708		
161	Lulling immunity, pain, and stress to sleep with cortistatin. *Annals of the New York Academy of Sciences*, **2015**, 1351, 89-98	6.5	15
160	Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis. *BioMed Research International*, **2015**, 2015, 681456	3	8
159	miR-335 correlates with senescence/aging in human mesenchymal stem cells and inhibits their therapeutic actions through inhibition of AP-1 activity. *Stem Cells*, **2014**, 32, 2229-44	5.8	52
158	Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model. *Stem Cells*, **2014**, 32, 1865-77	5.8	119
157	Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation. *Stem Cell Reports*, **2014**, 3, 606-19	8	27
156	Therapeutic effect of human amniotic membrane-derived cells on experimental arthritis and other inflammatory disorders. *Arthritis and Rheumatology*, **2014**, 66, 327-39	9.5	65
155	Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38. *EMBO Journal*, **2014**, 33, 1117-33	13	22
154	Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. *Haematologica*, **2014**, 99, 1168-75	6.6	32
153	Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens. *Journal of Biological Chemistry*, **2014**, 289, 14583-99	5.4	30
152	Peripheral nerve reconstruction with epsilon-caprolactone conduits seeded with vasoactive intestinal peptide gene-transfected mesenchymal stem cells in a rat model. *Journal of Neural Engineering*, **2014**, 11, 046024	5	7
151	Mesenchymal stem cells induce the ramification of microglia via the small RhoGTPases Cdc42 and Rac1. *Glia*, **2014**, 62, 1932-42	9	35
150	Cortistatin attenuates inflammatory pain via spinal and peripheral actions. *Neurobiology of Disease*, **2014**, 63, 141-54	7.5	23
149	Therapeutic application of mesenchymal stromal cells in murine models of inflammatory bowel disease. *Methods in Molecular Biology*, **2014**, 1213, 331-9	1.4	4
148	Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. *Amino Acids*, **2013**, 45, 25-39	3.5	97
147	Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. *Gut*, **2013**, 62, 1131-41	19.2	157
146	Analgesic effect of the neuropeptide cortistatin in murine models of arthritic inflammatory pain. *Arthritis and Rheumatism*, **2013**, 65, 1390-401		20

145	LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2179	4.8	19
144	Immunoregulatory Neuropeptides **2013**, 640-648		
143	Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation. *Circulation Research*, **2013**, 112, 1444-55	15.7	43
142	Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. *Cell Transplantation*, **2013**, 22, 839-54	4	34
141	PACAP **2013**, 1527-1534		
140	Preconditioning of microglia by □synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. *PLoS ONE*, **2013**, 8, e79160	3.7	69
139	NPSR1 gene is associated with reduced risk of rheumatoid arthritis. *Journal of Rheumatology*, **2012**, 39, 1166-70	4.1	9
138	Potential applications of vasoactive intestinal Peptide-based therapies on transplantation. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2012**, 12, 333-43	2.2	2
137	Vasoactive Intestinal Peptide: Immune Mediator and Potential Therapeutic Agent **2012**, 257-288		
136	Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. *Stem Cells*, **2011**, 29, 251-62	5.8	94
135	Neuropeptides as therapeutic approach to autoimmune diseases. *Current Pharmaceutical Design*, **2010**, 16, 3158-72	3.3	15
134	Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. *Molecular Therapy*, **2010**, 18, 1035-45	11.7	58
133	Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 540-8	10.2	116
132	Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. *Current Opinion in Pharmacology*, **2010**, 10, 473-81	5.1	29
131	Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2010**, 69, 241-8	2.4	311
130	Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson□s disease-linked mutants. *PLoS ONE*, **2010**, 5, e13481	3.7	74
129	Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. *Tissue Engineering - Part A*, **2009**, 15, 2795-806	3.9	199
128	Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. *Arthritis and Rheumatism*, **2009**, 60, 1006-19		407

127	Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. *Cell Death and Differentiation*, **2009**, 16, 406-16	12.7	67
126	Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. *Gut*, **2009**, 58, 929-39	19.2	482
125	Generating tolerogenic dendritic cells with neuropeptides. *Human Immunology*, **2009**, 70, 300-7	2.3	17
124	Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. *Gastroenterology*, **2009**, 136, 978-89	13.3	486
123	Immunotherapy for neurological diseases. *Clinical Immunology*, **2008**, 128, 294-305	9	42
122	Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 1830-47	5.6	19
121	Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. *Brain, Behavior, and Immunity*, **2008**, 22, 35-41	16.6	36
120	Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. *Brain, Behavior, and Immunity*, **2008**, 22, 1146-51	16.6	92
119	Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. *American Journal of Pathology*, **2008**, 172, 1297-307	5.8	62
118	Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders. *Molecular and Cellular Endocrinology*, **2008**, 286, 135-40	4.4	25
117	Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. *Journal of Immunology*, **2008**, 180, 8369-77	5.3	114
116	Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. *Annals of the Rheumatic Diseases*, **2008**, 67, 1235-41	2.4	31
115	Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. *Glia*, **2008**, 56, 1091-103	9	71
114	In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. *Arthritis and Rheumatism*, **2008**, 58, 1026-37		42
113	Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. *Arthritis and Rheumatism*, **2008**, 58, 1010-9		45
112	N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. *World Journal of Gastroenterology*, **2008**, 14, 2851-7	5.6	34
111	Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. *Arthritis and Rheumatism*, **2007**, 56, 531-43		57
110	Regulation of immune tolerance by anti-inflammatory neuropeptides. *Nature Reviews Immunology*, **2007**, 7, 52-63	36.5	181

109	Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. *Current Pharmaceutical Design*, **2007**, 13, 1113-39	3.3	72
108	Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. *Annals of the Rheumatic Diseases*, **2007**, 66, 582-8	2.4	59
107	Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?. *Trends in Pharmacological Sciences*, **2007**, 28, 482-91	13.2	43
106	Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. *Peptides*, **2007**, 28, 1833-46	3.8	30
105	Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. *Trends in Molecular Medicine*, **2007**, 13, 241-51	11.5	58
104	Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. *Annals of the Rheumatic Diseases*, **2007**, 66 Suppl 3, iii70-6	2.4	25
103	Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. *American Journal of Pathology*, **2007**, 170, 263-71	5.8	50
102	Tuning inflammation with anti-inflammatory neuropeptides. *Expert Opinion on Biological Therapy*, **2007**, 7, 461-78	5.4	18
101	Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. *PLoS ONE*, **2007**, 2, e1071	3.7	35
100	Vasoactive Intestinal Peptide: An Anti-inflammatory Neuropeptide **2007**, 131-157		
99	A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells. *Journal of NeuroImmune Pharmacology*, **2006**, 1, 400-9	6.9	28
98	Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. *Arthritis and Rheumatism*, **2006**, 54, 864-76		89
97	Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. *European Journal of Immunology*, **2006**, 36, 318-26	6.1	74
96	Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. *Gut*, **2006**, 55, 824-32	19.2	86
95	Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. *Journal of Experimental Medicine*, **2006**, 203, 563-71	16.6	134
94	Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 4228-33	11.5	89
93	Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. *Journal of Immunology*, **2006**, 176, 97-110	5.3	55
92	Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. *American Journal of Pathology*, **2006**, 168, 1179-88	5.8	86

91	Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. *American Journal of Pathology*, **2006**, 168, 1921-30	5.8	71
90	Therapeutic action of ghrelin in a mouse model of colitis. *Gastroenterology*, **2006**, 130, 1707-20	13.3	208
89	Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. *Gastroenterology*, **2006**, 131, 1799-811	13.3	80
88	Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. *Regulatory Peptides*, **2006**, 137, 67-74		28
87	Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. *Blood*, **2006**, 107, 3787-94	2.2	81
86	Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. *Blood*, **2006**, 107, 3632-8	2.2	122
85	Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. *Annals of the New York Academy of Sciences*, **2006**, 1070, 190-5	6.5	17
84	Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation. *Annals of the New York Academy of Sciences*, **2006**, 1070, 226-32	6.5	8
83	Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis. *Annals of the New York Academy of Sciences*, **2006**, 1070, 233-8	6.5	27
82	VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. *Annals of the New York Academy of Sciences*, **2006**, 1070, 276-81	6.5	27
81	VIP: an agent with license to kill infective parasites. *Annals of the New York Academy of Sciences*, **2006**, 1070, 303-8	6.5	19
80	Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. *Annals of the New York Academy of Sciences*, **2006**, 1070, 337-41	6.5	22
79	VIP protects Th2 cells by downregulating granzyme B expression. *Annals of the New York Academy of Sciences*, **2006**, 1070, 540-4	6.5	5
78	Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation. *Annals of the New York Academy of Sciences*, **2006**, 1088, 187-94	6.5	22
77	Cortistatin as a potential multistep therapeutic agent for inflammatory disorders. *Drug News and Perspectives*, **2006**, 19, 393-9		10
76	Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. *Expert Opinion on Therapeutic Targets*, **2005**, 9, 923-9	6.4	9
75	Analysis of a GT microsatellite in the promoter of the foxp3/scurfin gene in autoimmune diseases. *Human Immunology*, **2005**, 66, 869-73	2.3	23
74	Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13562-7	11.5	137

73	The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. *Journal of Immunology*, **2005**, 175, 7311-24	5.3	117
72	Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. *Journal of Leukocyte Biology*, **2005**, 78, 1327-38	6.5	83
71	The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. *FASEB Journal*, **2004** , 18, 1325-34	0.9	78
70	VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. *FASEB Journal*, **2004**, 18, 1453-5	0.9	88
69	VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. *Journal of Leukocyte Biology*, **2004**, 75, 1122-30	6.5	67
68	The significance of vasoactive intestinal peptide in immunomodulation. *Pharmacological Reviews*, **2004**, 56, 249-90	22.5	325
67	Role of Neuropeptides in T-Cell Differentiation **2004**, 289-304		
66	VIP and PACAP Immune Mediators Involved in Homeostasis and Disease **2004**, 263-283		
65	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. *Journal of Leukocyte Biology*, **2003**, 73, 155-64	6.5	105
64	PACAP in immunity and inflammation. *Annals of the New York Academy of Sciences*, **2003**, 992, 141-57	6.5	101
63	Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. *Gastroenterology*, **2003**, 124, 961-71	13.3	217
62	Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. *Biochemical and Biophysical Research Communications*, **2003**, 301, 825-32	3.4	27
61	Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. *Biochemical and Biophysical Research Communications*, **2003**, 302, 275-83	3.4	35
60	VIP: a very important peptide in T helper differentiation. *Trends in Immunology*, **2003**, 24, 221-4	14.4	47
59	Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. *FASEB Journal*, **2003**, 17, 1922-4	0.9	89
58	Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. *Journal of Biological Chemistry*, **2003**, 278, 27620-9	5.4	60
57	Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. *FASEB Journal*, **2003**, 17, 944-6	0.9	123
56	The neuropeptides VIP/PACAP and T cells: inhibitors or activators?. *Current Pharmaceutical Design*, **2003**, 9, 997-1004	3.3	37

55	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. *Glia*, **2002**, 39, 148-61	9	116
54	Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. *Journal of Molecular Medicine*, **2002**, 80, 16-24	5.5	133
53	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. *Critical Reviews in Oral Biology and Medicine*, **2002**, 13, 229-37		113
52	Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 1053-8	11.5	103
51	Pituitary adenylate-cyclase-activating polypeptide expression in the immune system. *NeuroImmunoModulation*, **2002**, 10, 177-86	2.5	45
50	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. *FASEB Journal*, **2002**, 16, 1844-6	0.9	54
49	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. *Biochemical and Biophysical Research Communications*, **2002**, 293, 771-6	3.4	48
48	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia. *Biochemical and Biophysical Research Communications*, **2002**, 297, 1181-5	3.4	41
47	Inhibitory neuropeptide receptors on macrophages. *Microbes and Infection*, **2001**, 3, 141-7	9.3	32
46	Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. *Nature Medicine*, **2001**, 7, 563-8	50.5	334
45	VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells. *Journal of Neuroimmunology*, **2001**, 112, 78-88	3.5	12
44	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. *Journal of Biological Chemistry*, **2001**, 276, 369-80	5.4	86
43	VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors. *Archives of Physiology and Biochemistry*, **2001**, 109, 372-6	2.2	14
42	Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. *Journal of Immunology*, **2001**, 167, 3182-9	5.3	55
41	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. *Journal of Immunology*, **2001**, 166, 1028-40	5.3	77
40	Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. *Journal of Immunology*, **2001**, 167, 966-75	5.3	107
39	Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?. *Journal of Immunology*, **2001**, 166, 2907-12	5.3	84
38	TH2 lymphocytes secrete functional VIP upon antigen stimulation. *Archives of Physiology and Biochemistry*, **2001**, 109, 365-8	2.2	26

37	Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. *Archives of Physiology and Biochemistry*, **2001**, 109, 377-82	2.2	28
36	Immunology of VIP: a review and therapeutical perspectives. *Current Pharmaceutical Design*, **2001**, 7, 89-111	3.3	145
35	VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. *Annals of the New York Academy of Sciences*, **2000**, 921, 55-67	6.5	29
34	VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. *Annals of the New York Academy of Sciences*, **2000**, 921, 68-78	6.5	28
33	Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. *Annals of the New York Academy of Sciences*, **2000**, 921, 92-102	6.5	53
32	Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. *European Journal of Immunology*, **2000**, 30, 3236-46	6.1	78
31	Immunobiology of vasoactive intestinal peptide (VIP). *Trends in Immunology*, **2000**, 21, 7-11		97
30	Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. *Journal of Neuroimmunology*, **2000**, 107, 88-99	3.5	27
29	Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. *Journal of Neuroimmunology*, **2000**, 110, 97-105	3.5	45
28	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. *Journal of Immunology*, **2000**, 165, 114-23	5.3	27
27	Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Journal of Immunology*, **2000**, 165, 3051-7	5.3	74
26	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. *Journal of Immunology*, **2000**, 164, 1200-10	5.3	51
25	Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. *NeuroImmunoModulation*, **1999**, 6, 97-107	2.5	34
24	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. *Journal of Biological Chemistry*, **1999**, 274, 31930-40	5.4	86
23	VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. *Annals of the New York Academy of Sciences*, **1999**, 897, 401-14	6.5	60
22	Regulation of VIP production and secretion by murine lymphocytes. *Journal of Neuroimmunology*, **1999**, 93, 126-38	3.5	105
21	VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. *Journal of Neuroimmunology*, **1999**, 96, 167-81	3.5	147
20	Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. *Journal of Neuroimmunology*, **1999**, 99, 61-71	3.5	37

19	VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. *Journal of Neuroimmunology*, **1998**, 85, 155-67	3.5	68
18	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. *Journal of Biological Chemistry*, **1998**, 273, 31427-36	5.4	138
17	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. *Journal of Leukocyte Biology* , **1998**, 63, 591-601	6.5	114
16	Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1997**, 1359, 250-62	4.9	48
15	Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. *Journal of Neuroimmunology*, **1996**, 68, 27-38	3.5	104
14	Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. *Journal of Neuroimmunology*, **1996**, 68, 109-19	3.5	50
13	Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. *Regulatory Peptides*, **1996**, 62, 161-6		46
12	Differential VIP and VIP1 receptor gene expression in rat thymocyte subsets. *Peptides*, **1996**, 17, 803-7	3.8	38
11	Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions. *Peptides*, **1996**, 17, 1097-105	3.8	29
10	Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. *Advances in Neuroimmunology*, **1996**, 6, 29-36		48
9	VIP modulation of immune cell functions. *Advances in Neuroimmunology*, **1996**, 6, 75-91		69
8	Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility. *Neuropeptides*, **1996**, 30, 583-95	3.3	29
7	Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. *Journal of Neuroimmunology*, **1995**, 62, 137-46	3.5	45
6	Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. *Regulatory Peptides*, **1994**, 50, 177-84		49
5	Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. *Peptides*, **1994**, 15, 791-8	3.8	39
4	Vasoactive intestinal peptide modulation of adherence and mobility in rat peritoneal lymphocytes and macrophages. *Peptides*, **1994**, 15, 1157-63	3.8	44
3	Gene expression of VIP receptor in rat lymphocytes. *Biochemical and Biophysical Research Communications*, **1994**, 203, 1599-604	3.4	42
2	VIP gene expression in rat thymus and spleen. *Brain, Behavior, and Immunity*, **1993**, 7, 271-8	16.6	44

1 Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function in rat macrophages. Protein kinase C involvement. *Regulatory Peptides*, **1993**, 48, 345-53 34